First Time Loading...

Eiger BioPharmaceuticals Inc
NASDAQ:EIGR

Watchlist Manager
Eiger BioPharmaceuticals Inc Logo
Eiger BioPharmaceuticals Inc
NASDAQ:EIGR
Watchlist
Price: 2.4 USD Market Closed
Updated: May 5, 2024
Section:
 

Relative Value

The Relative Value of one EIGR stock under the Base Case scenario is 124.61 USD. Compared to the current market price of 2.4 USD, Eiger BioPharmaceuticals Inc is Undervalued by 98%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EIGR Relative Value
Base Case
124.61 USD
Undervaluation 98%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.2
P/S
P/S
Price to Sales
0.2
vs History
57
vs Industry
94
Median 3Y
376.2
Median 5Y
27.7
Industry
8.3
Forward
0.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-73.6
Median 5Y
-119
Industry
26.8
Forward
-0.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-64
Median 5Y
-111.5
Industry
23.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-61.3
Median 5Y
-115
Industry
21.4
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
73
Median 3Y
64.7
Median 5Y
82.1
Industry
2.6
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
83
Median 3Y
370.9
Median 5Y
27.8
Industry
7.5
Forward
-0.9
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
81
Median 3Y
395
Median 5Y
28.3
Industry
9.2
More Details
0.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.3
vs History
1
vs Industry
22
Median 3Y
-58.7
Median 5Y
-100.4
Industry
4.5
More Details
0.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.3
vs History
1
vs Industry
21
Median 3Y
-58.5
Median 5Y
-100.3
Industry
4.4
More Details
0.3
EV/OCF
EV/OCF
Enterprise Value to OCF
0.3
vs History
1
vs Industry
24
Median 3Y
-63.1
Median 5Y
-110
Industry
5.6
More Details
0.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.3
vs History
1
vs Industry
20
Median 3Y
-62.9
Median 5Y
-109.7
Industry
3.4
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
70
Median 3Y
148.3
Median 5Y
728.6
Industry
5
More Details

Multiples Across Competitors

EIGR Competitors Multiples
Eiger BioPharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eiger BioPharmaceuticals Inc
NASDAQ:EIGR
3.6m USD 0.2 -0 0.3 0.3
US
Abbvie Inc
NYSE:ABBV
289.2B USD 5.3 60 13 19.9
US
Amgen Inc
NASDAQ:AMGN
166.7B USD 5.9 24.8 17.9 26.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
104.7B USD 8 26.5 17.8 19.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.4B USD 10.5 28.6 22.8 23.9
AU
CSL Ltd
ASX:CSL
133.2B AUD 6.2 35.6 21.6 26.7
US
Gilead Sciences Inc
NASDAQ:GILD
80.7B USD 2.9 166.8 6.7 8.8
US
Moderna Inc
NASDAQ:MRNA
47.8B USD 7 -10.1 -11 -9.4
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.7B USD 3.3 27.1 13.9 17.4
KR
Celltrion Inc
KRX:068270
39.2T KRW 18 73.1 44.7 61.6

See Also

Summary
EIGR intrinsic value, competitors valuation, and company profile.
DCF Valuation
EIGR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EIGR stock valuation using valuation multiples.
Wall Street Estimates
EIGR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EIGR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.